Literature DB >> 20464463

Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease.

Mritunjay Pandey1, Kochupurackal P Mohanakumar, Rajamma Usha.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease which is characterized by psychiatric symptoms, involuntary choreiform movements and dementia with maximum degeneration occurring in striatum and cerebral cortex. Several studies implicate mitochondrial dysfunction to the selective neurodegeneration happening in this disorder. Calcium buffering imbalance and oxidative stress in the mitochondria, critically impaired movement across axons and abnormal fission or fusion of this organelle in the cells are some of the salient features that results in the loss of mitochondrial electron transport chain (ETC) complex function in HD. Although several models involving mutant huntingtin, excitotoxins and mitochondrial complex-II inhibitors have been used to explore the disease, it is not clear how disturbances in mitochondrial functioning is associated with such selective neurodegeneration, or in the expression of huntingtonian phenotypes in animals or man. We have carefully assessed various mitochondrial abnormalities observed in human patient samples, postmortem HD brains, cellular, vertebrate and invertebrate models of the disease, to conclude that ETC dysfunction is an integral part of the disease and justify a causal role of mitochondrial ETC dysfunction for the genesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464463     DOI: 10.1007/s10863-010-9288-5

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  110 in total

1.  Loss of mitochondrial membrane potential is associated with increase in mitochondrial volume: physiological role in neurones.

Authors:  Dzhamilja Safiulina; Vladimir Veksler; Alexander Zharkovsky; Allen Kaasik
Journal:  J Cell Physiol       Date:  2006-02       Impact factor: 6.384

2.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

3.  Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.

Authors:  S Krobitsch; S Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

4.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.

Authors:  Alexandra Benchoua; Yaël Trioulier; Diana Zala; Marie-Claude Gaillard; Nathalie Lefort; Noelle Dufour; Frederic Saudou; Jean-Marc Elalouf; Etienne Hirsch; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

5.  The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Authors:  Erica Rockabrand; Natalia Slepko; Antonello Pantalone; Vidya N Nukala; Aleksey Kazantsev; J Lawrence Marsh; Patrick G Sullivan; Joan S Steffan; Stefano L Sensi; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

6.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-13       Impact factor: 6.150

7.  Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.

Authors:  Karina Acevedo-Torres; Lexsy Berríos; Nydia Rosario; Vanessa Dufault; Serguei Skatchkov; Misty J Eaton; Carlos A Torres-Ramos; Sylvette Ayala-Torres
Journal:  DNA Repair (Amst)       Date:  2008-11-20

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

10.  Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.

Authors:  Mritunjay Pandey; Anupom Borah; Merina Varghese; Pijus Kanti Barman; Kochupurackal P Mohanakumar; Rajamma Usha
Journal:  Neurochem Int       Date:  2009-05-04       Impact factor: 3.921

View more
  9 in total

Review 1.  Cell signaling and mitochondrial dynamics: Implications for neuronal function and neurodegenerative disease.

Authors:  Theodore J Wilson; Andrew M Slupe; Stefan Strack
Journal:  Neurobiol Dis       Date:  2012-01-24       Impact factor: 5.996

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Mitochondria: the next (neurode)generation.

Authors:  Eric A Schon; Serge Przedborski
Journal:  Neuron       Date:  2011-06-23       Impact factor: 17.173

Review 4.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 5.  Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel.

Authors:  Andrew P Wojtovich; C Owen Smith; Cole M Haynes; Keith W Nehrke; Paul S Brookes
Journal:  Biochim Biophys Acta       Date:  2013-01-02

Review 6.  Mitochondrial matters in Huntington disease.

Authors:  George H Sack
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

7.  Oxytocin Prevents the Development of 3-NP-Induced Anxiety and Depression in Male and Female Rats: Possible Interaction of OXTR and mGluR2.

Authors:  Fariba Khodagholi; Ali Maleki; Fereshteh Motamedi; Maryam Alsadat Mousavi; Shahrbanoo Rafiei; Mehdi Moslemi
Journal:  Cell Mol Neurobiol       Date:  2020-11-17       Impact factor: 5.046

8.  Distribution of GABAergic interneurons and dopaminergic cells in the functional territories of the human striatum.

Authors:  Javier Bernácer; Lucía Prensa; José Manuel Giménez-Amaya
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

9.  The Association of VDAC with Cell Viability of PC12 Model of Huntington's Disease.

Authors:  Andonis Karachitos; Daria Grobys; Klaudia Kulczyńska; Adrian Sobusiak; Hanna Kmita
Journal:  Front Oncol       Date:  2016-11-11       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.